Prescribing information

 

   

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

Cosentyx has been helping patients since 20151

In 2021, we reached a massively significant milestone that would barely have seemed possible just a few short years ago.2

Watch the video below to see just how far we’ve come…

 

To learn more about why you should choose Cosentyx, click here

References

  1. Bloomberg. Novartis Pharma AG: Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic. Available at: https://www.bloomberg.com/press-releases/2022-05-20/novartis-pharma-ag-n... expanded-use-in-childhood-arthritic [Last accessed June 2022].
  2. Data on File Sec004. Novartis Pharmaceuticals Corp; 2019.
Rate this content: 
No votes yet
UK | June 2022 | 218104
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]